FACT Complex-targeting Curaxin CBL0137

Identifier: CI-DRUG-00000230
Entity page: /drug/fact-complex-targeting-curaxin-cbl0137 ↗
Edges: 18

Neighbours: 12 cancers1 variants5 trials
Drawn: 18 of 18 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
FACT Complex-targeting Curaxin CBL0137 predicts response to …PREDICTS_RESPONSE_TO1 of 1
← predicts response to	MYCN Amplificationamplification	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
FACT Complex-targeting Curaxin CBL0137 investigated for …INVESTIGATED_FOR1 of 1
investigated for

FACT Complex-targeting Curaxin CBL0137 investigated in trials for …INVESTIGATED_IN_TRIALSderived11 of 11
→ investigated in trials for	Cutaneous Melanoma of the Extremity 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cutaneous Melanoma of the Extremity	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Diffuse Intrinsic Pontine Glioma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Intrinsic Pontine Glioma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Diffuse Midline Glioma, H3 K27-Altered 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Midline Glioma, H3 K27-Altered	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Glioblastoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Hematopoietic and Lymphoid Cell Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hematopoietic and Lymphoid Cell Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Lymphoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Solid Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Melanoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Sarcoma of the Extremity 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Sarcoma of the Extremity	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Soft Tissue Sarcoma of the Trunk and Extremities 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Soft Tissue Sarcoma of the Trunk and Extremities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →

FACT Complex-targeting Curaxin CBL0137 investigated in trials for …INVESTIGATED_IN_TRIALSderived11 of 11

→ investigated in trials for

Cutaneous Melanoma of the Extremity

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Cutaneous Melanoma of the Extremity

Observed

FACT Complex-targeting Curaxin CBL0137 studied in …STUDIED_INderived5 of 5
→ studied in	NCT04870944Phase 1/Phase 2 · recruiting CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma · 5 trials list this drug (2 active)	—	—	Lymphoma,Malignant Solid Neoplasm,Diffuse Intrinsic Pontine Glioma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT05498792early Phase 1 · recruiting Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma · 5 trials list this drug (2 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03727789Phase 1 · terminated CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma · 5 trials list this drug (2 active)	—	—	Sarcoma of the Extremity,Cutaneous Melanoma of the Extremity,Soft Tissue Sarcoma of the Trunk and Extremities	1	Observed	clinicaltrials	graph →
→ studied in	NCT01905228Phase 1 · completed A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm · 5 trials list this drug (2 active)	—	—	Solid Neoplasm,Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02931110Phase 1 · terminated Study of IV CBL0137 in Previously Treated Hematological Subjects · 5 trials list this drug (2 active)	—	—	Hematopoietic and Lymphoid Cell Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths